|
1
|
Uehara E, Takeuchi S, Yang Y, et al:
Aberrant methylation in promoter-associated CpG islands of multiple
genes in chronic myelogenous leukemia blast crisis. Oncol Lett.
3:190–192. 2012.PubMed/NCBI
|
|
2
|
Cortes J and Kantarjian H: How I treat
newly diagnosed chronic phase CML. Blood. 120:1390–1397. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Deans RJ and Moseley AB: Mesenchymal stem
cells: biology and potential clinical uses. Exp Hematol.
28:875–884. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jiang Y, Jahagirdar BN, Reinhardt RL, et
al: Pluripotency of mesenchymal stem cells derived from adult
marrow. Nature. 418:41–49. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Barry FP and Murphy JM: Mesenchymal stem
cells: clinical applications and biological characterization. Int J
Biochem Cell Biol. 36:568–584. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bianchi G, Borgonovo G, Pistoia V and
Raffaghello L: Immunosuppressive cells and tumour microenvironment:
focus on mesenchymal stem cells and myeloid derived suppressor
cells. Histol Histopathol. 26:941–951. 2011.PubMed/NCBI
|
|
7
|
Prockop DJ: Marrow stromal cells as stem
cells for nonhematopoietic tissues. Science. 276:71–74. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Granero-Molto F, Weis JA, Longobardi L and
Spagnoli A: Role of mesenchymal stem cells in regenerative
medicine: application to bone and cartilage repair. Expert Opin
Biol Ther. 8:255–268. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Salem HK and Thiemermann C: Mesenchymal
stromal cells: current understanding and clinical status. Stem
Cells. 28:585–596. 2010.PubMed/NCBI
|
|
10
|
Dezawa M, Ishikawa H, Itokazu Y, et al:
Bone marrow stromal cells generate muscle cells and repair muscle
degeneration. Science. 309:314–317. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Oostendorp RA and Dörmer P: VLA-4-mediated
interactions between normal human hematopoietic progenitors and
stromal cells. Leuk Lymphoma. 24:423–435. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Colmone A, Amorim M and Pontier AL:
Leukemic cells create bone marrow niches that disrupt the behavior
of normal hematopoietic progenitor cells. Science. 322:1861–1865.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Duarte RF and Frank DA: SCF and G-CSF lead
to the synergistic induction of proliferation and gene expression
through complementary signaling pathways. Blood. 96:3422–3430.
2000.PubMed/NCBI
|
|
14
|
Frick JS, Zahir N, Mulier M, et al:
Colitogenic and non-colitogenic commensal bacteria differentially
trigger DC maturation and Th cell polarization: an important role
for IL-6. Eur J Immunol. 36:1537–1547. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bandini G, Zuffa E, Rosti G, et al:
Long-term outcome of adults with acute myelogenous leukaemia:
results of a prospective, randomized study of chemotherapy with a
minimal follow-up of 7 years. Br J Haematol. 77:486–490.
1991.PubMed/NCBI
|
|
16
|
Zhu Y, Sun Z, Han Q, et al: Human
mesenchymal stem cells inhibit cancer cell proliferation by
secreting DKK-1. Leukemia. 23:925–933. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Moshaver B, van der Pol MA, Westra AH, et
al: Chemotherapeutic treatment of bone marrow stromal cells
strongly affects their protective effect on acute myeloid leukemia
cell survival. Leuk Lymphoma. 49:134–148. 2008. View Article : Google Scholar
|
|
18
|
Gaundar SS, Bradstock KF and Bendall LJ:
p38MAPK inhibitors attenuate cytokine production by bone marrow
stromal cells and reduce stroma-mediated proliferation of acute
lymphoblastic leukemia cells. Cell Cycle. 8:2975–2983. 2009.
View Article : Google Scholar
|
|
19
|
Konopleva M and Andreeff M: Targeting the
leukemia microenvironment. Curr Drug Targets. 8:685–701. 2007.
View Article : Google Scholar
|
|
20
|
Nefedova Y, Landowski TH and Dalton WS:
Bone marrow stromal-derived soluble factors and direct cell contact
contribute to de novo drug resistance of myeloma cells by distinct
mechanisms. Leukemia. 17:1175–1182. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Konopleva M, Konoplev S, Hu W, et al:
Stromal cells prevent apoptosis of AML cells by up-regulation of
anti-apoptotic proteins. Leukemia. 16:1713–1724. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yeung J, Esposito MT, Gandillet A, et al:
β-Catenin mediates the establishment and drug resistance of MLL
leukemic stem cells. Cancer Cell. 18:606–618. 2010.
|
|
23
|
Sheth K, Friel J, Nolan B and Bankey P:
Inhibition of p38 mitogen activated protein kinase increases
lipopolysaccharide induced inhibition of apoptosis in neutrophils
by activating extracellular signal-regulated kinase. Surgery.
130:242–248. 2001. View Article : Google Scholar
|
|
24
|
Grandage VL, Gale RE, Linch DC and Khwaja
A: PI3-kinase/Akt is constitutively active in primary acute myeloid
leukaemia cells and regulates survival and chemoresistance via
NF-kappaB, Mapkinase and p53 pathways. Leukemia. 19:586–594.
2005.PubMed/NCBI
|
|
25
|
Valencia A, Román-Gómez J, Cervera J, et
al: Wnt signaling pathway is epigenetically regulated by
methylation of Wnt antagonists in acute myeloid leukemia. Leukemia.
23:1658–1666. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Radich JP, Dai H, Mao M, et al: Gene
expression changes associated with progression and response in
chronic myeloid leukemia. Proc Natl Acad Sci USA. 103:2794–2799.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hu Y, Chen Y, Douglas L and Li S:
Beta-Catenin is essential for survival of leukemic stem cells
insensitive to kinase inhibition in mice with BCR-ABL-induced
chronic myeloid leukemia. Leukemia. 23:109–116. 2009. View Article : Google Scholar : PubMed/NCBI
|
